---
title: "Skyrizi (risankizumab-rzaa), all indications: Safety questions"
description: "Safety questions on Skyrizi (risankizumab-rzaa) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings. Questions: Does Skyrizi increase the risk of infections? Do patients need a TB test before starting Skyrizi? Can Skyrizi cause liver problems? Does Skyrizi have a boxed warning? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/skyrizi/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa), all indications: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)

## Warnings

<a id="skyrizi-infections"></a>

### Does Skyrizi increase the risk of infections?

> “SKYRIZI may increase the risk of infections [see Adverse Reactions (6.1)].  
> Treatment with SKYRIZI should not be initiated in patients with any clinically important active 
> infection until the infection resolves or is adequately treated. 
> In patients with a chronic infection or a history of recurrent infection, consider the risks and 
> benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or 
> symptoms of clinically important infection occur. If a patient develops such an infection or is not 
> responding to standard therapy, monitor the patient closely and do not administer SKYRIZI until 
> the infection resolves.”

Source: [SKYRIZI: Prescribing information, page 8, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=8)

> “Infections: In the first 16 weeks, infections occurred in 22.1% of the SKYRIZI group (90.8 
> events per 100 patient-years) compared with 14.7% of the placebo group (56.5 events per 100 
> patient-years) and did not lead to discontinuation of SKYRIZI. The rates of serious infections for 
> the SKYRIZI group and the placebo group were ≤0.4%. Serious infections in the SKYRIZI 
> group included cellulitis, osteomyelitis, sepsis, and herpes zoster. In Trials PsO-1 and PsO-2, 
> through Week 52, the rate of infections (73.9 events per 100 patient-years) was similar to the rate 
> observed during the first 16 weeks of treatment.”

Source: [SKYRIZI: Prescribing information, page 10, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=10)

<a id="skyrizi-tuberculosis"></a>

### Do patients need a TB test before starting Skyrizi?

> “Consider evaluating patients for tuberculosis (TB) infection prior to initiating treatment with 
> SKYRIZI based on clinical judgement. Consider anti-TB therapy prior to initiating SKYRIZI in 
> patients with a past history of latent or active TB in whom an adequate course of treatment 
> cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after 
> SKYRIZI treatment. Avoid administering SKYRIZI to patients with active TB.”

Source: [SKYRIZI: Prescribing information, page 8, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=8)

> “Consider evaluating patients for tuberculosis (TB) prior to initiation based on clinical judgment. Instruct patients to report signs and symptoms of infection.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=Consider%20evaluating%20patients%20for%20tuberculosis,signs%20and%20symptoms%20of%20infection.)

Note: The adult administration instructions on the dosing page of the Skyrizi HCP site say to evaluate patients for TB infection before starting Skyrizi; the Prescribing Information and the safety page say to consider evaluation based on clinical judgement.

<a id="skyrizi-liver"></a>

### Can Skyrizi cause liver problems?

> “A serious adverse reaction of drug-induced liver injury in conjunction with a rash that required 
> hospitalization was reported in a patient with Crohn’s disease (ALT 54x ULN, AST 30x ULN, 
> and total bilirubin 2.2x ULN) following two 600 mg intravenous doses of SKYRIZI. The liver 
> test abnormalities resolved following administration of steroids. SKYRIZI was subsequently 
> discontinued. 
> For the treatment of Crohn’s disease and ulcerative colitis, evaluate liver enzymes and bilirubin 
> at baseline, and during induction at least up to 12 weeks of treatment. Monitor thereafter 
> according to routine patient management.  
> Consider other treatment options in patients with evidence of liver cirrhosis.  
> Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential 
> cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected,”

Source: [SKYRIZI: Prescribing information, page 8, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=8)

> “until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they 
> experience symptoms suggestive of hepatic dysfunction.”

Source: [SKYRIZI: Prescribing information, page 9, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=9)

> “Additionally, in the Phase 3 placebo-controlled trials the incidence of hepatic events was higher 
> in the SKYRIZI group (5.4%, 16.7 events per 100 patient-years) compared to the placebo group 
> (3.9%, 12.6 events per 100 patient-years). Of these, the most common events that were reported 
> more frequently in both the placebo group and the SKYRIZI group were ALT increased 
> (placebo: n=12 (1.7%); SKYRIZI: n=16 (2.3%)), AST increased (placebo: n=9 (1.3%); 
> SKYRIZI: n=13 (1.8%)), and GGT increased (placebo: n=5 (0.7%); SKYRIZI: n=8 (1.1%)). 
> There were no serious hepatic events reported.”

Source: [SKYRIZI: Prescribing information, page 11, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=11)

> “Inform patients that SKYRIZI may cause liver injury, especially during the initial 12 weeks of 
> treatment. Instruct patients to seek immediate medical attention if they experience symptoms 
> suggestive of liver dysfunction (e.g., unexplained rash, nausea, vomiting, abdominal pain, 
> fatigue, anorexia, or jaundice and/or dark urine) [see Warnings and Precautions (5.4)].”

Source: [SKYRIZI: Prescribing information, page 42, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=42)

Note: The first two passages are section 5.4 of the Prescribing Information, which continues across a page break. The liver test schedule in the label applies to Crohn’s disease and ulcerative colitis; the hepatic event rates are from the psoriatic arthritis trials. The safety page of the Skyrizi HCP site lists the warnings and precautions as hypersensitivity, infections, tuberculosis, and immunizations; the current Prescribing Information also lists hepatotoxicity (5.4).

<a id="skyrizi-boxed-warning"></a>

### Does Skyrizi have a boxed warning?

> “NO
>
> labeled boxedwarning”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=depression%2C%20or%20candidiasis1-,NO,labeled)

> “Safety Considerations: SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reactions to risankizumab-rzaa or any of its excipients. Warnings and precautions include hypersensitivity, infections, TB, and immunizations.<sup>1</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=Safety%20Considerations%3A%20SKYRIZI%20is%20contraindicated,include%20hypersensitivity%2C%20infections%2C%20TB%2C%20and)

> “The following adverse reactions are discussed in other sections of labeling:  
> • Hypersensitivity Reactions [see Warnings and Precautions (5.1)] 
> • Infections [see Warnings and Precautions (5.2)] 
> • Tuberculosis [see Warnings and Precautions (5.3)] 
> • Hepatotoxicity [see Warnings and Precautions (5.4)]”

Source: [SKYRIZI: Prescribing information, page 9, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=9)

Note: The safety page names four warnings and precautions; the current Prescribing Information also lists hepatotoxicity (5.4), described for a patient with Crohn’s disease.

<a id="skyrizi-cancer-warning"></a>

### Does Skyrizi have a cancer warning?

> “NO
>
> labeled warnings or precautions for malignancy, IBD, depression, or candidiasis<sup>1</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=NO,for%20malignancy%2C%20IBD%2C%20depression%2C%20or)

> “The following adverse reactions are discussed in other sections of labeling:  
> • Hypersensitivity Reactions [see Warnings and Precautions (5.1)] 
> • Infections [see Warnings and Precautions (5.2)] 
> • Tuberculosis [see Warnings and Precautions (5.3)] 
> • Hepatotoxicity [see Warnings and Precautions (5.4)]”

Source: [SKYRIZI: Prescribing information, page 9, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=9)

<a id="skyrizi-contraindications-allergy"></a>

### Who should not take Skyrizi (contraindications)?

> “SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to 
> risankizumab-rzaa or any of the excipients [see Warnings and Precautions (5.1)].”

Source: [SKYRIZI: Prescribing information, page 8, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=8)

<a id="skyrizi-allergic-reactions"></a>

### Can Skyrizi cause allergic reactions or anaphylaxis?

> “Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of 
> SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate 
> appropriate therapy immediately [see Adverse Reactions (6.1)].”

Source: [SKYRIZI: Prescribing information, page 8, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=8)

> “Adverse reactions that occurred in < 1% but > 0.1% of subjects in the SKYRIZI group and at a 
> higher rate than in the placebo group through Week 16 were folliculitis and urticaria.”

Source: [SKYRIZI: Prescribing information, page 10, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=10)

<a id="skyrizi-vaccines"></a>

### Can patients on Skyrizi get vaccines, including live vaccines?

> “Avoid use of live vaccines in patients treated with SKYRIZI. Drugs that interact with the 
> immune system may increase the risk of infection following administration of live vaccines. 
> Prior to initiating therapy with SKYRIZI, complete all age-appropriate vaccinations according to 
> current immunization guidelines. No data are available on the response to live or inactive 
> vaccines.”

Source: [SKYRIZI: Prescribing information, page 9, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=9)

> “Advise patients that vaccination with live vaccines is not recommended during SKYRIZI 
> treatment and immediately prior to or after SKYRIZI treatment. Medications that interact with 
> the immune system may increase the risk of infection following administration of live vaccines. 
> Instruct patients to inform the healthcare practitioner that they are taking SKYRIZI prior to a 
> potential vaccination [see Warnings and Precautions (5.5)].”

Source: [SKYRIZI: Prescribing information, page 43, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=43)

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): All indications](https://www.evicenter.com/medical-information/skyrizi)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/skyrizi/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi/storage-and-supply)
